

# Cynthia Forlini

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9004950/publications.pdf>

Version: 2024-02-01

50  
papers

1,188  
citations

394286

19  
h-index

395590

33  
g-index

53  
all docs

53  
docs citations

53  
times ranked

1142  
citing authors

#	ARTICLE	IF	CITATIONS
1	Problematic risk-taking involving emerging technologies: A stakeholder framework to minimize harms. <i>Journal of Behavioral Addictions</i> , 2021, 9, 869-875.	1.9	15
2	The pharmaceuticalisation of "healthy" ageing: Testosterone enhancement for longevity. <i>International Journal of Drug Policy</i> , 2021, 95, 103159.	1.6	20
3	Death determination, organ donation and the importance of the Dead Donor Rule following withdrawal of life-sustaining treatment: A survey of community opinions. <i>Internal Medicine Journal</i> , 2021, , .	0.5	1
4	A scoping review of the perceptions of death in the context of organ donation and transplantation. <i>BMC Medical Ethics</i> , 2021, 22, 167.	1.0	13
5	Empirical Data Is Failing to Break the Ethics Stalemate in the Cognitive Enhancement Debate. <i>AJOB Neuroscience</i> , 2020, 11, 240-242.	0.6	4
6	Death, dying and donation: community perceptions of brain death and their relationship to decisions regarding withdrawal of vital organ support and organ donation. <i>Internal Medicine Journal</i> , 2020, 50, 1192-1201.	0.5	7
7	Seeking legitimacy for broad understandings of substance use. <i>International Journal of Drug Policy</i> , 2019, 73, 58-63.	1.6	28
8	An Australian community jury to consider case-finding for dementia: Differences between informed community preferences and general practice guidelines. <i>Health Expectations</i> , 2019, 22, 475-484.	1.1	10
9	A Neuroethics Framework for the Australian Brain Initiative. <i>Neuron</i> , 2019, 101, 365-369.	3.8	11
10	Beyond Flourishing: Intersecting Uses and Interests in the Neurotechnology Marketplace. <i>AJOB Neuroscience</i> , 2019, 10, 178-180.	0.6	3
11	Non-medical prescription stimulant use to improve academic performance among Australian university students: prevalence and correlates of use. <i>BMC Public Health</i> , 2018, 18, 1270.	1.2	21
12	Surveillance Medicine in the Digital Era: Lessons From Addiction Treatment. <i>American Journal of Bioethics</i> , 2018, 18, 58-60.	0.5	5
13	Public Mental Health Ethics: Helping Improve Mental Health for Individuals and Communities. <i>Public Health Ethics</i> , 2018, 11, 121-125.	0.4	4
14	A prospectus for ethical analysis of ageing individuals' responsibility to prevent cognitive decline. <i>Bioethics</i> , 2017, 31, 657-665.	0.7	4
15	Throwing the Ethics (Hand)Book at Professional Organizations in the Neurological Sciences. <i>AJOB Neuroscience</i> , 2017, 8, W1-W2.	0.6	1
16	Contextualized Autonomy and Liberalism: Broadening the Lenses on Complementary and Alternative Medicines in Preclinical Alzheimer's Disease. <i>Kennedy Institute of Ethics Journal</i> , 2017, 27, 1-41.	0.3	12
17	Patient Preferences May Be Indicative of Normative Issues in Dementia Research. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 11-12.	1.2	0
18	The is and ought of the Ethics of Neuroenhancement: Mind the Gap. <i>Frontiers in Psychology</i> , 2016, 6, 1998.	1.1	15

#	ARTICLE	IF	CITATIONS
19	Australian University Studentsâ€™ Coping Strategies and Use of Pharmaceutical Stimulants as Cognitive Enhancers. <i>Frontiers in Psychology</i> , 2016, 7, 277.	1.1	44
20	Complementary and Alternative Medicine in the Context of Earlier Diagnoses of Alzheimerâ€™s Disease: Opening the Conversation to Prepare Ethical Responses. <i>Journal of Alzheimer's Disease</i> , 2016, 51, 1-9.	1.2	6
21	The Hidden Ethics Curriculum in Two Canadian Psychiatry Residency Programs: A Qualitative Study. <i>Academic Psychiatry</i> , 2016, 40, 592-599.	0.4	11
22	Cognitive Enhancement Down-Under. , 2016, , 147-158.		1
23	Ethical issues raised by a ban on the sale of electronic nicotine devices. <i>Addiction</i> , 2015, 110, 1061-1067.	1.7	40
24	Ethical, Social and Clinical Challenges in using Deep Brain Stimulation to Treat Addiction and Other Impulsive and Compulsive Disorders. <i>Jahrbuch FÃ¼r Wissenschaft Und Ethik</i> , 2015, 19, 163-188.	0.3	0
25	Researchersâ€™ perspectives on scientific and ethical issues with transcranial direct current stimulation: An international survey. <i>Scientific Reports</i> , 2015, 5, 10618.	1.6	31
26	Nuances in the ethical regulation of electronic nicotine delivery systems. <i>Addiction</i> , 2015, 110, 1074-1075.	1.7	2
27	The brain disease model of addiction: is it supported by the evidence and has it delivered on its promises?. <i>Lancet Psychiatry</i> ,the, 2015, 2, 105-110.	3.7	158
28	The brain disease model of addiction: challenging or reinforcing stigma?â€™“Authors' reply. <i>Lancet Psychiatry</i> ,the, 2015, 2, 292.	3.7	6
29	Brain disease model of addiction: misplaced priorities?. <i>Lancet Psychiatry</i> ,the, 2015, 2, 867.	3.7	22
30	Knowledge, Experiences and Views of German University Students Toward Neuroenhancement: An Empirical-Ethical Analysis. <i>Neuroethics</i> , 2015, 8, 83-92.	1.7	32
31	Using Neuropharmaceuticals for Cognitive Enhancement: Policy and Regulatory Issues. , 2015, , 1085-1100.		3
32	Popular Media and Bioethics Scholarship: Sharing Responsibility for Portrayals of Cognitive Enhancement with Prescription Medications. , 2015, , 1473-1486.		5
33	Food Addiction and Its Impact on Weight-Based Stigma and the Treatment of Obese Individuals in the U.S. and Australia. <i>Nutrients</i> , 2014, 6, 5312-5326.	1.7	68
34	Alienation and Authenticity in Parkinson's Disease and Its Treatment. <i>AJOB Neuroscience</i> , 2014, 5, 54-56.	0.6	2
35	The value and pitfalls of speculation about science and technology in bioethics: the case of cognitive enhancement. <i>Medicine, Health Care and Philosophy</i> , 2014, 17, 325-337.	0.9	38
36	Generating genius: how an Alzheimerâ€™s drug became considered a â€™cognitive enhancerâ€™ for healthy individuals. <i>BMC Medical Ethics</i> , 2014, 15, 37.	1.0	17

#	ARTICLE	IF	CITATIONS
37	Navigating the enhancement landscape. EMBO Reports, 2013, 14, 123-128.	2.0	25
38	Should physicians prescribe cognitive enhancers to healthy individuals?. Cmaj, 2013, 185, 1047-1050.	0.9	41
39	How Research on Stakeholder Perspectives Can Inform Policy on Cognitive Enhancement. American Journal of Bioethics, 2013, 13, 41-43.	0.5	8
40	Does the Cognitive Enhancement Debate Call for a Renewal of the Deliberative Role of Bioethics?. Trends in Augmentation of Human Performance, 2013, , 173-186.	0.4	5
41	Impact of Contextual Factors and Substance Characteristics on Perspectives toward Cognitive Enhancement. PLoS ONE, 2013, 8, e71452.	1.1	50
42	Stakeholder perspectives and reactions to "academic" cognitive enhancement: Unsuspected meaning of ambivalence and analogies. Public Understanding of Science, 2012, 21, 606-625.	1.6	42
43	Added Stakeholders, Added Value(s) to the Cognitive Enhancement Debate: Are Academic Discourse and Professional Policies Sidestepping Values of Stakeholders?. American Journal of Bioethics Primary Research, 2012, 3, 33-47.	1.5	32
44	Considering the Causes and Implications of Ambivalence in Using Medicine for Enhancement. American Journal of Bioethics, 2011, 11, 15-17.	0.5	9
45	Cognitive Enhancement, Lifestyle Choice or Misuse of Prescription Drugs?. Neuroethics, 2010, 3, 1-4.	1.7	94
46	RESPONDING TO REQUESTS FROM ADULT PATIENTS FOR NEUROENHANCEMENTS: GUIDANCE OF THE ETHICS, LAW AND HUMANITIES COMMITTEE. Neurology, 2010, 74, 1555-1556.	1.5	12
47	Expectations regarding cognitive enhancement create substantial challenges. Journal of Medical Ethics, 2009, 35, 469-470.	1.0	28
48	Autonomy and Coercion in Academic "Cognitive Enhancement" Using Methylphenidate: Perspectives of Key Stakeholders. Neuroethics, 2009, 2, 163-177.	1.7	110
49	Disagreements with implications: diverging discourses on the ethics of non-medical use of methylphenidate for performance enhancement. BMC Medical Ethics, 2009, 10, 9.	1.0	67
50	The Hidden Curriculum in Ethics and its Relationship to Professional Identity Formation: A Qualitative Study of Two Canadian Psychiatry Residency Programs. Canadian Journal of Bioethics, 0, 3, 80-92.	0.0	1